{"id":70092,"date":"2026-07-16T16:21:34","date_gmt":"2026-07-16T08:21:34","guid":{"rendered":"https:\/\/flcube.com\/?p=70092"},"modified":"2026-07-16T16:21:35","modified_gmt":"2026-07-16T08:21:35","slug":"china-medical-system-secures-nmpa-approval-for-cms-d017-novel-complement-factor-b-inhibitor-for-amd","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70092","title":{"rendered":"China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>China Medical System Holdings Limited (CMS)<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/0867:HKG\">HKG: 0867<\/a>) announced today that the <strong>National Medical Products Administration (NMPA)<\/strong> has approved the clinical trial application for <strong>CMS-D017 capsules<\/strong>, an innovative <strong>complement factor B inhibitor<\/strong> self-developed by the Group for the treatment of <strong>age-related macular degeneration (AMD)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-key-details\" class=\"wp-block-heading\">Regulatory Milestone | Key Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>China Medical System Holdings Limited (CMS) (HKG: 0867)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>CMS-D017 capsules<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial application approval<\/td><\/tr><tr><td><strong>Primary Indication<\/strong><\/td><td>Age-related macular degeneration (AMD)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>July 15, 2026<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical to Phase I transition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-molecular-characteristics\" class=\"wp-block-heading\">Molecular Characteristics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Selective complement factor B inhibitor<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Oral capsules<\/li>\n\n\n\n<li><strong>Development Status:<\/strong> Self-developed by CMS Group<\/li>\n\n\n\n<li><strong>Target Specificity:<\/strong> Complement factor B in alternative complement pathway<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-biological-rationale\" class=\"wp-block-heading\">Biological Rationale<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">CMS-D017 works through a targeted mechanism to address complement-mediated diseases:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Selective inhibition<\/strong> of complement factor B<\/li>\n\n\n\n<li><strong>Blocks abnormal activation<\/strong> of the alternative complement pathway<\/li>\n\n\n\n<li><strong>Reduces membrane attack complex (MAC)-mediated damage<\/strong> to target tissues and organs<\/li>\n\n\n\n<li><strong>Slows disease progression<\/strong> in AMD and other complement-mediated disorders<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-preclinical-evidence\" class=\"wp-block-heading\">Preclinical Evidence<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacy:<\/strong> Demonstrated promising therapeutic activity in preclinical models<\/li>\n\n\n\n<li><strong>Safety:<\/strong> Favorable safety profile with no significant toxicity concerns identified<\/li>\n\n\n\n<li><strong>Therapeutic Window:<\/strong> Adequate exposure levels achieved with oral administration<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-target-indications-amp-market-opportunity\" class=\"wp-block-heading\">Target Indications &amp; Market Opportunity<\/h2>\n\n\n\n<h3 id=\"h-primary-focus-age-related-macular-degeneration-amd\" class=\"wp-block-heading\">Primary Focus: Age-Related Macular Degeneration (AMD)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence:<\/strong> Affects over <strong>200 million people globally<\/strong>, with incidence increasing with aging populations<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Limited treatment options for dry AMD; current therapies primarily address wet AMD<\/li>\n\n\n\n<li><strong>Market Size:<\/strong> Global AMD therapeutics market projected to reach <strong>$15 billion by 2030<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-additional-indications\" class=\"wp-block-heading\">Additional Indications<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">CMS-D017 is designed for multiple complement-mediated disorders:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Complement-mediated kidney diseases<\/strong> (e.g., C3 glomerulopathy, atypical hemolytic uremic syndrome)<\/li>\n\n\n\n<li><strong>Paroxysmal nocturnal hemoglobinuria (PNH)<\/strong> \u2013 rare but serious blood disorder<\/li>\n\n\n\n<li><strong>Other complement-mediated conditions<\/strong> with similar pathophysiological mechanisms<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance-for-cms\" class=\"wp-block-heading\">Strategic Significance for CMS<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This approval represents a significant milestone in CMS&#8217;s strategic pivot toward <strong>innovative drug development<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-in-class potential<\/strong> in China for complement factor B inhibition<\/li>\n\n\n\n<li><strong>Global intellectual property<\/strong> position as self-developed asset<\/li>\n\n\n\n<li><strong>Diversification<\/strong> beyond traditional pharmaceutical distribution business<\/li>\n\n\n\n<li><strong>Pipeline expansion<\/strong> into high-value specialty therapeutic areas<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The complement pathway has emerged as a <strong>validated therapeutic target<\/strong> following successes with drugs like eculizumab and ravulizumab, but oral small molecule inhibitors like CMS-D017 offer potential advantages in terms of <strong>administration convenience, cost-effectiveness, and broader patient access<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape\" class=\"wp-block-heading\">Competitive Landscape<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The complement inhibitor market is dominated by <strong>monoclonal antibodies<\/strong> requiring intravenous or subcutaneous administration. CMS-D017&#8217;s <strong>oral formulation<\/strong> could provide significant differentiation:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient preference<\/strong> for oral vs. injectable therapies<\/li>\n\n\n\n<li><strong>Reduced healthcare burden<\/strong> from elimination of infusion requirements<\/li>\n\n\n\n<li><strong>Potential for earlier intervention<\/strong> in disease progression due to improved accessibility<\/li>\n\n\n\n<li><strong>Cost advantages<\/strong> compared to biologic complement inhibitors<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">If successful in clinical development, CMS-D017 could become the <strong>first oral complement factor B inhibitor<\/strong> approved in China, positioning CMS as an innovator in this emerging therapeutic class.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071500928_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026071500928_c.\"><\/object><a id=\"wp-block-file--media-4c356c03-5f30-4b69-866c-a5fbdfd976cc\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071500928_c.pdf\">2026071500928_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071500928_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4c356c03-5f30-4b69-866c-a5fbdfd976cc\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China Medical System Holdings Limited (CMS) (HKG: 0867) announced today that the National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[325,62,844,44],"class_list":["post-70092","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-china-medical-system","tag-clinical-trial-approval-initiation","tag-hkg-0867","tag-ophthalmology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Medical System Holdings Limited (CMS) (HKG: 0867) announced today that the National Medical Products Administration (NMPA) has approved the clinical trial application for CMS-D017 capsules, an innovative complement factor B inhibitor self-developed by the Group for the treatment of age-related macular degeneration (AMD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70092\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD\" \/>\n<meta property=\"og:description\" content=\"China Medical System Holdings Limited (CMS) (HKG: 0867) announced today that the National Medical Products Administration (NMPA) has approved the clinical trial application for CMS-D017 capsules, an innovative complement factor B inhibitor self-developed by the Group for the treatment of age-related macular degeneration (AMD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70092\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T08:21:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T08:21:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70092#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70092\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD\",\"datePublished\":\"2026-07-16T08:21:34+00:00\",\"dateModified\":\"2026-07-16T08:21:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70092\"},\"wordCount\":502,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"China Medical System\",\"Clinical trial approval \\\/ initiation\",\"HKG: 0867\",\"Ophthalmology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70092#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70092\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70092\",\"name\":\"China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-16T08:21:34+00:00\",\"dateModified\":\"2026-07-16T08:21:35+00:00\",\"description\":\"China Medical System Holdings Limited (CMS) (HKG: 0867) announced today that the National Medical Products Administration (NMPA) has approved the clinical trial application for CMS-D017 capsules, an innovative complement factor B inhibitor self-developed by the Group for the treatment of age-related macular degeneration (AMD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70092#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70092\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70092#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD - Insight, China&#039;s Pharmaceutical Industry","description":"China Medical System Holdings Limited (CMS) (HKG: 0867) announced today that the National Medical Products Administration (NMPA) has approved the clinical trial application for CMS-D017 capsules, an innovative complement factor B inhibitor self-developed by the Group for the treatment of age-related macular degeneration (AMD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70092","og_locale":"en_US","og_type":"article","og_title":"China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD","og_description":"China Medical System Holdings Limited (CMS) (HKG: 0867) announced today that the National Medical Products Administration (NMPA) has approved the clinical trial application for CMS-D017 capsules, an innovative complement factor B inhibitor self-developed by the Group for the treatment of age-related macular degeneration (AMD).","og_url":"https:\/\/flcube.com\/?p=70092","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-16T08:21:34+00:00","article_modified_time":"2026-07-16T08:21:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70092#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70092"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD","datePublished":"2026-07-16T08:21:34+00:00","dateModified":"2026-07-16T08:21:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70092"},"wordCount":502,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["China Medical System","Clinical trial approval \/ initiation","HKG: 0867","Ophthalmology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70092#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70092","url":"https:\/\/flcube.com\/?p=70092","name":"China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-16T08:21:34+00:00","dateModified":"2026-07-16T08:21:35+00:00","description":"China Medical System Holdings Limited (CMS) (HKG: 0867) announced today that the National Medical Products Administration (NMPA) has approved the clinical trial application for CMS-D017 capsules, an innovative complement factor B inhibitor self-developed by the Group for the treatment of age-related macular degeneration (AMD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70092#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70092"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70092#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70092"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70092\/revisions"}],"predecessor-version":[{"id":70094,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70092\/revisions\/70094"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}